Fuming Li

This study shows BET inhibition in liver cancer reduces proliferation by inducing GDH1-dependent glutamine metabolic changes, suggesting a therapeutic strategy combining BET and OXPHOS inhibitors.

The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.

The paper identifies FBP1 as a nonenzymatic regulator that inhibits AKT activation to prevent insulin hyperresponsiveness and associated liver pathologies.